ArticleIntractable & rare diseases research2025
Challenges in Japan's dual systems of support for pediatric and adult intractable diseases.
Article in Intractable & rare diseases research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From system building to global engagement: Current significance of and future directions for rare disease research in China.Intractable & rare diseases research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Japan has developed two separate frameworks to support patients with chronic and rare diseases: the Specified Pediatric Chronic Diseases (SPCD) Program and the Designated Intractable Diseases (DID) System. Although both aim to provide medical and social assistance, they differ in age of eligibility, diseases covered, and administrative procedures. The SPCD Program provides support to individuals under 18 years of age (extendable to 20) with 858 eligible conditions, whereas the DID System, with 348 designated diseases, applies to all ages. These structural discrepancies create a critical policy gap when pediatric patients transition into adulthood. Those whose conditions are not listed under the DID System lose their eligibility for public subsidies, resulting in sudden financial strain and reduced social participation. Additional issues include inconsistencies in diagnostic criteria, limited access to transitional care facilities -currently established in only 12 prefectures -and insufficient family-centered support, especially for siblings acting as young carers. To achieve continuity of care and equity, Japan must harmonize disease definitions and transition criteria, introduce temporary relief measures for non-designated patients, increase the number of Transitional Care Support Centers in regions, and institutionalize family-inclusive assistance. Establishing a seamless policy framework over a patient's life will not only encourage patients' independence but also strengthen the sustainability of Japan's healthcare system in the face of an aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.